FDA 483 - Theragen, Inc - February 20, 2020

An FDA inspection of Theragen, Inc, a medical device manufacturer in Manassas, VA, identified one observation related to inadequate documentation of corrective and preventive action (CAPA) activities. Specifically, a CAPA remained open despite a verification effectiveness check being completed. This indicates a deficiency in the firm's quality system regarding CAPA management.